105 results
8-K
EX-99
PFE
Pfizer Inc.
1 May 24
Pfizer Reports First-Quarter 2024 Results
8:11am
in unexpected costs, organizational disruption, adverse effects on employee morale, retention issues or other unintended consequences;
the ability
8-K
EX-99
PFE
Pfizer Inc.
30 Jan 24
Pfizer Reports Full-Year 2023 Results and Reaffirms Full-Year 2024 Financial Guidance
8:04am
effects on employee morale, retention issues or other unintended consequences;
the ability to successfully achieve our climate goals and progress our
8-K
EX-1.1
PFE
Pfizer Inc.
19 May 23
Other Events
4:26pm
with the Commission or retention where required and legending; and
(c) Each of the Issuer and the Guarantor agrees that if at any time following issuance
8-K
EX-1.1
2qa2b6
18 Aug 21
Other Events
4:06pm
8-K
gbg938835657 zu
13 Nov 20
Unregistered Sales of Equity Securities
5:05pm
8-K
EX-99.1
3g1mrmva7rx 3o6thw8l
5 Nov 20
Pfizer Announces Details for When-Issued and Ex-Distribution Trading of Viatris and Pfizer Common Stock
4:42pm
8-K
EX-99.1
yl52t8
30 Oct 20
Mylan and Pfizer Receive Clearance from the U.S. Federal Trade Commission for Proposed Combination of Mylan and Upjohn
5:10pm
8-K
1vqbz cdfj2ze
6 Aug 20
Regulation FD Disclosure
5:23pm
8-K
EX-99.1
anogimvg7 8a2jbqqy
6 Aug 20
Regulation FD Disclosure
5:23pm
425
y2oboxy
26 Jun 20
Business combination disclosure
5:05pm
8-K
x0gwqk
26 Jun 20
Other Events
5:03pm
425
d84ou
18 Jun 20
Business combination disclosure
5:01pm
425
q8z5o9ii4b 5q2j
1 Jun 20
Business combination disclosure
5:27pm
8-K
5vfuu ede
1 Jun 20
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-2.2
gmqigax9rd5oztssa
1 Jun 20
Entry into a Material Definitive Agreement
5:25pm
8-K
EX-1.1
3p5ua uyj5700jlegfl
19 May 20
Pfizer Prices $4,000,000,000 Debt Offering
4:30pm